Jan 04, 2021 7:00am EST Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma
Dec 17, 2020 7:00am EST Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma
Dec 15, 2020 7:00am EST Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers
Oct 29, 2020 3:59pm EDT Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress
Oct 22, 2020 7:00am EDT Lantern Pharma to Host Third Quarter 2020 Operating and Financial Results Conference Call on October 29, 2020 at 4:00 p.m. ET
Oct 05, 2020 7:46am EDT Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent
Sep 22, 2020 7:55am EDT Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer
